I 

116TH CONGRESS 

2D SESSION H. R. 7104 

To direct the Secretary of Health and Human Services to award contracts, 

grants, and cooperative agreements to expand and enhance manufacturing capacity of vaccines and vaccine candidates to prevent the spread 

of SARS–CoV–2 and COVID–19. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 4, 2020 

Ms. KUSTER of New Hampshire (for herself and Mr. JEFFRIES) introduced 

the following bill; which was referred to the Committee on Energy and 

Commerce 

A BILL 

To direct the Secretary of Health and Human Services to 

award contracts, grants, and cooperative agreements to 

expand and enhance manufacturing capacity of vaccines 

and vaccine candidates to prevent the spread of SARS– 

CoV–2 and COVID–19. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. VACCINE MANUFACTURING AND ADMINISTRA4 TION CAPACITY. 

5 (a) ENHANCING MANUFACTURING CAPACITY.— 

6 (1) IN GENERAL.—The Secretary of Health and 

7 Human Services (in this section referred to as the 


ctelli on DSK30NT082PROD with BILLS
2 

•HR 7104 IH

1 ‘‘Secretary’’) acting through the Director of the Bio2 medical Advanced Research and Development Au3 thority shall, as appropriate, award contracts, 

4 grants, and cooperative agreements, and enter into 

5 other transactions, to expand and enhance manufac6 turing capacity of vaccines and vaccine candidates to 

7 prevent the spread of SARS–CoV–2 and COVID–19. 

8 (2) AUTHORIZATION OF APPROPRIATIONS.—To 

9 carry out this subsection, there are authorized to be 

10 appropriated such sums as may be necessary for fis11 cal years 2020 through 2024, to remain available 

12 until expended. 

13 (b) REPORT ON VACCINE MANUFACTURING AND AD14 MINISTRATION CAPACITY.— 

15 (1) IN GENERAL.—Not later than December 31, 

16 2020, the Secretary shall submit to the Committee 

17 on Energy and Commerce of the House of Rep18 resentatives and the Committee on Health, Edu19 cation, Labor and Pensions of the Senate a report 

20 detailing— 

21 (A) an assessment of the estimated supply 

22 of vaccines and ancillary medical products re23 lated to vaccine administration necessary to 

24 control and stop the spread of SARS–CoV–2 


ctelli on DSK30NT082PROD with BILLS
3 

•HR 7104 IH

1 and COVID–19, domestically and internation2 ally; 

3 (B) an assessment of current and future 

4 domestic manufacturing capacity for vaccines or 

5 vaccine candidates to control or stop the spread 

6 of SARS–CoV–2 and COVID–19, vaccine can7 didates, and ancillary products related to the 

8 administration of such vaccines, including iden9 tification of any gaps in manufacturing capac10 ity; 

11 (C) activities conducted to expand and en12 hance manufacturing capacity for vaccines, vac13 cine candidates, and ancillary medical products 

14 to levels sufficient to control and stop the 

15 spread of SARS–CoV–2 and COVID–19, do16 mestically and internationally, including a list 

17 and explanation of all contracts, grants, and co18 operative agreements awarded, and other trans19 actions entered into, for purposes of such ex20 pansion and enhancement and how such activi21 ties will help to meet future domestic manufac22 turing capacity needs; 

23 (D) a plan for the ongoing support of en24 hanced manufacturing capacity for vaccines, 

25 vaccine candidates, and ancillary medical prodVerDate Sep 11 2014 04:14 Jun 24, 2020 Jkt 099200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H7104.IH H7104

ctelli on DSK30NT082PROD with BILLS
4 

•HR 7104 IH

1 ucts sufficient to control and stop the spread of 

2 SARS–CoV–2 and COVID–19, domestically 

3 and internationally; and 

4 (E) a plan to support the administration of 

5 vaccines approved or authorized by the Food 

6 and Drug Administration to control and stop 

7 the spread of SARS–CoV–2 and COVID–19, 

8 domestically and internationally, including Fed9 eral workforce enhancements necessary to ad10 minister such vaccines. 

11 (2) ANCILLARY MEDICAL PRODUCTS.—For pur12 poses of this subsection, ‘‘ancillary medical prod13 ucts’’ includes— 

14 (A) vials; 

15 (B) bandages; 

16 (C) alcohol swabs; 

17 (D) syringes; 

18 (E) needles; 

19 (F) gloves and other personal protective 

20 equipment; and 

21 (G) other medical products the Secretary 

22 determines necessary for the administration of 

23 vaccines. 

Æ 


ctelli on DSK30NT082PROD with BILLS